Phase 1Completed
Study of TJ011133 in Participants With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma
- Sponsor
- I-Mab Biopharma US Limited (Industry)
- Enrollment
- 98 enrolled
- Conditions
- Solid Tumor; Lymphoma
- Interventions
- TJ011133; Pembrolizumab; Rituximab
- Ages
- adults, older adults
- Registry
- NCT03934814
Full record on ClinicalTrials.gov
From the registry
The purpose of this study is to assess the safety and tolerability of TJ011133 in participants with solid tumors and lymphoma.
Primary outcomes
- Dose Limiting Toxicities (DLT)
- Incidence and Severity of Adverse Events
- Maximum Tolerated Dose (MTD) for Both Monotherapy and Combination Therapy
- Change in Eastern Cooperative Oncology Group (ECOG) Performance Status
History
Last registry update
Primary completion
Registered
Started